TRIZIVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trizivir, and when can generic versions of Trizivir launch?
Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.
The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
Summary for TRIZIVIR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Clinical Trials: | 20 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TRIZIVIR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRIZIVIR |
What excipients (inactive ingredients) are in TRIZIVIR? | TRIZIVIR excipients list |
DailyMed Link: | TRIZIVIR at DailyMed |
Recent Clinical Trials for TRIZIVIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
AIDS Clinical Trials Group | Phase 3 |
National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
Ines Perez | Phase 4 |
Pharmacology for TRIZIVIR
Anatomical Therapeutic Chemical (ATC) Classes for TRIZIVIR
Paragraph IV (Patent) Challenges for TRIZIVIR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TRIZIVIR | Tablets | abacavir sulfate; lamivudine; zidovudine | 300 mg/150 mg/ 300 mg | 021205 | 1 | 2011-03-22 |
US Patents and Regulatory Information for TRIZIVIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIZIVIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIZIVIR
See the table below for patents covering TRIZIVIR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 80035 | ⤷ Try a Trial | |
African Regional IP Organization (ARIPO) | 101 | Therapeutic Nucleosides | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 9852571 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TRIZIVIR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0382526 | 19675032 | Germany | ⤷ Try a Trial | PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228 |
0817637 | SPC/GB05/027 | United Kingdom | ⤷ Try a Trial | SPC/GB05/027: 20050922, EXPIRES: 20191216 |
0817637 | 288 | Finland | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |